– USA, CA – Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of current Board member Julie Eastland as President and CEO, effective November 8, 2021, succeeding Dr. Jerry McMahon who has resigned from his position as President and CEO and the Board of Directors.
Concurrently, Board member Scott Myers has been named Chair of the Board of Directors.
“We are very pleased that Julie Eastland will lead the Harpoon Therapeutics team as we advance our clinical programs and seek to maximize opportunities for our TriTAC, ProTriTAC, and TriTAC-XR T cell engager technology platforms,” said Board Chair, Scott Myers.
He added: “I am looking forward to my new role as Chair and having worked with Julie in the past at other biotech companies spanning early to late-stage development programs, I am confident that her leadership and operational expertise in clinical oncology, immunology, and other therapeutic categories is an excellent fit for Harpoon at this point in its development.”
About Julie Eastland
Julie Eastland joined the Harpoon Board in 2018 and her career spans more than 20 years of executive leadership in the biotechnology industry. Most recently she served as COO and CFO of ReCode Therapeutics, a private genetic medicines company developing therapeutics using its proprietary lipid nanoparticle delivery technology to target organs and tissues beyond the liver. Before ReCode, she served as CFO and CBO of Rainier Therapeutics, a private biopharmaceutical company focused on FGFR3 bladder cancer. Before Rainier, she served as CFO and CBO of Cascadian Therapeutics, a publicly-traded oncology company that was acquired by Seattle Genetics in 2018. Before Cascadian, she held various financial and strategic management positions at public and private biotechnology companies including VLST Corporation, Dendreon, and Amgen.
“I am excited to lead Harpoon Therapeutics as its next President and CEO and to champion the company’s clinical programs targeting new breakthrough treatments for cancer,” commented Julie Eastland. “I look forward to working alongside the medical and scientific teams to advance Harpoon’s novel immuno-oncology therapeutic modalities through the clinic and ultimately to commercialization, to make a difference in the lives of patients with cancer.”
Ms. Eastland received an MBA from Heriot-Watt University of the Edinburgh University in Scotland and a B.S. in finance from Colorado State University.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary tri-specific T cell Activating Construct platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor.
For more information: https://www.harpoontx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.